SARS-CoV-2 Safety Study for the Treatment of COVID-19 (SARS-CoV-2)

August 24, 2025 updated by: Do Van Tin, DHA Coffee Co., Ltd
SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells.

CHEMISTRY:

SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives.

Toxicology:

SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology.

SARS-CoV-2 is not placebo drug

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Vietnam
      • Ho Chi Minh City, Vietnam, 84
        • Do Van Tin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • SARS-CoV-2

Exclusion Criteria:

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SARS-CoV-2 Safety Study for the Treatment of COVID-19

Directions: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).
Drug: HIV

Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.

Humidification: <5% Dosage Form:

Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date

Other Names:
  • HIV Safety Study for the Treatment of Anti-AIDS Drug
Drug: Malignant Neoplasms Safety Study for the Treatment of Neoplasms
Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.
Other Names:
  • Malignant Neoplasms

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SARS-CoV-2
Time Frame: From September to October, 2024
  1. Parameters: Humidification, Unit: %, Result: 4.40, Test Method: ISO 7932: 2004.
  2. Cadmium (Cd), mg/Kg, 0.1, CASE.TN.0018 (Ref. AOAC 999.11).
  3. Hydrargyrum (Hg), mg/Kg, 0.01, CASE.TN.0141 (Ref . EPA Method 7473).
  4. Plumbum (Pb), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017.
  5. Cadmium (Cd), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. .
  6. Arsen (As), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017.
  7. Hydrargyrum (Hg), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017.
  8. Clostridium perfringents, CFU/g, < 10, ISO 7937:2004.
  9. Coliforms, CFU/g, < 10, ISO 4832:2006 (*).
  10. Escherichia coli, CFU/g, < 10, ISO 7937:2006.
  11. Salmonella, /25g, Not detected, ISO 7937:2007.
  12. Staphylococcus aureus, CFU/g, < 10, ISO 7937:2008.
  13. Total Yeasts molds, CFU/g, < 10, ISO 7937:2009.
  14. Total Aerobic Microbial, CFU/g, 1.0 x 100, ISO 7937:2010.
  15. Vibrio parahaemolyticuc, /25g, Not detected, ISO 7937:2011. .
From September to October, 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

DHA Coffee Co., Ltd

Investigators

  • Principal Investigator: PHUOC T DO, DHA Coffee Co., Ltd

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 28, 2025

Primary Completion (Estimated)

January 30, 2025

Study Completion (Estimated)

February 4, 2025

Study Registration Dates

First Submitted

March 5, 2024

First Submitted That Met QC Criteria

July 4, 2024

First Posted (Actual)

July 8, 2024

Study Record Updates

Last Update Posted (Estimated)

September 4, 2025

Last Update Submitted That Met QC Criteria

August 24, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DHACoffee

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

20 -1 g Packets Net Weight 0.70 oz (20 g) Directions: For adults and for Children 1-12 years old. Indication: Treated the SARS-CoV-2 treatment COVID-19 within 20 days Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Use within two years from the manufacturing date. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SARS-CoV-2

Clinical Trials on HIV

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe